HLA Typing for Transplant Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing transplants volume worldwide, rising number of transplant & diagnostic centers, technological advancements, government initiatives to boost HLA typing services, rising public -private investments boost research in HLA genotyping, and increased focus of players to enhance their manufacturing & distribution capabilities across emerging countries are likely to support the growth of HLA typing for transplant market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

In the near future, HLA typing is poised to revolutionize the transplant industry. Rapid advancements in genomics and precision medicine will enable transplant professionals to intricately match donor and recipient HLA profiles, significantly reducing the risk of rejection and the need for immunosuppressive drugs. This breakthrough technology will expand the pool of potential donors, improve transplant success rates, and usher in a new era of life-saving organ and tissue transplantation, offering hope to countless patients awaiting these life-changing procedures.

Key Market Players of HLA Typing for Transplant Industry:

Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US),  Luminex Corporation (US), TBG Diagnostics Limited. (Australia) FUJIREBIO (Japan),Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742

HLA Typing for Transplant Market Dynamics:

Drivers:

·         Increasing number of transplant procedures globally

Restraints:

·         costs of molecular tests used for HLA typing procedures

Opportunities:

·         Technological shift from non-molecular serological assays to gene-based HLA profiling

Challenge:

·         Significant gap between organ availability and demand

This research report categorizes the HLA typing for transplant market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

·         Reagents & Consumables

·         Instruments

·         Software & Services

By Technology

·         Molecular Assay Technologies

o   PCR-Based Molecular Assays

§  Real-time PCR

§  Sequence-specific Primer-PCR

§  Sequence-specific Oligonucleotide-PCR

§  Other PCR-based Molecular Assays

o   Sequencing-based Molecular Assays

§  Sanger Sequencing

§  Next-generation Sequencing

§  Other Sequencing-based Molecular Assays

o   Non-molecular Assay Technologies

By Application

·         Diagnostic Applications

·         Antibody Screening

·         Chimerism Monitoring

·         Others

·         Research Applications

By Transplant Type

·         Solid Organ Transplant

·         Soft Tissue Transplant

By End User

·         Independent Reference Laboratories

·         Hospitals & Transplant Centers

·         Research Laboratories & Academic Institutes

By Region

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle-East Africa

Recent Developments:

·         In September 2023, Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com